
WEST PHARMACEUTICAL SERVICES
WSTNYSETrading Snapshot
- Day Range
- $346.81 โ $357.88
- 52-Week Range
- $223.83 โ $386.00
- Volume
- $3.15B
- Avg Volume
- $2.65B
- Shares Outstanding
- 70.4M
- Next Earnings
- Oct 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $3.07B
- Last Q Revenue
- $872M
- P/E Ratio
- 44.1
- P/S Ratio
- 7.5x
- EPS (TTM)
- $7.82
- Dividend Yield
- 0.25%
Why Investors Own WST
- โHigh-growth profile โ revenue up -3.0% YoY with expanding US Equity exposure.
- โHealthy economics โ 55% gross margin and 29% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About WEST PHARMACEUTICAL SERVICES
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith โ a cyclic olefin polymer used in vials, syringes, and cartridges โ and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates

Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut
INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.

iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised
IRTC posts 20.1% revenue growth, margin expansion and a higher 2026 outlook while advancing innovation and its Vital Connect acquisition.

Top 50 High-Quality Dividend Growth Stocks For August 2026
I track a curated universe of 50 high-quality dividend growth stocks to identify timely, attractive entry points for long-term total return. Check out the list here.

Cisco Stock Is Finally Pricing In A New Growth Story
Management put a much higher number on its future, and the stock has been on a tear ever since. But is this a fleeting AI boom or a fundamental rewiring of the business.

XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales
DENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.

AMN Q2 Earnings Beat Estimates on Staffing and Search Growth, Stock Up
AMN Healthcare's Q2 EPS jumps 158% as revenues rise 2.3%, helped by travel nurse, allied and search growth plus labor disruption activity.